Tuning the Immune System to Fight Cancer
Our mission is to empower cancer patients’ immune defenses to fight cancer and to equip them with durable protection to prevent recurrence
Tuning the Immune System to Fight Cancer
Our mission is to empower cancer patients’ immune defenses to fight cancer and to equip them with durable protection to prevent recurrence
Our approach
Proprietary Technology
NeoVAC, our main product in development, which is aimed to enter the clinic in 2020, is developed utilizing our proprietary PersoVax™, AmpliVax™, Pyrovant™ and CADVax™ technologies.
Unique Differentiators
DNA-based vaccines offer distinct advantages for immunotherapy over other approaches such as peptide/RNA vaccines, or cell-based immunotherapies.
Company Highlights
About Us
Company Background
Immunetune, based in Leiden, the Netherlands, is a dedicated and fast-moving biotech company committed to develop personalized, tumor-specific vaccines to fight cancer and prevent its recurrence.
News
Biotech Wednesday: Joining forces to outsmart cancer
Immunetune will be attending Biotech Wednesday on November 20 in Utrecht, the Netherlands. Reach out to us through the networking app or contact us directly in case you'd like to learn more about Immunetune's approach to fight cancer. More information on this meeting...
Neoantigen Summit, 20-22 Nov in Boston
CSO Jeroen van Bergen will be presenting key highlights of Immunetune's preclinical proof-of-concept results at the Neoantigen summit in Boston, USA on November 20-22, 2019.
Bio-Europe, Nov 11-13 in Hamburg
Gerben C.M. Zondag, CEO of Immunetune, will attend the BIO-Europe meeting in Hamburg, November 11-13, 2019. Feel free to request a meeting if you'd like to hear more about possible partnering of investment opportunities.